Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection

LAKE FOREST, Ill., Jan. 19, 2016 — (Healthcare Sales & Marketing Network) — Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8… Biopharmaceuticals, Generics, Product LaunchAkorn, Buprenorphine, Naloxone, Tobramycin (Source: HSMN NewsFeed)

Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. (Source: Addiction)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Malmö Treatment Referral and Intervention Study (MATRIS)—effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. (Source: Addiction)

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder. (Source: Journal of Clinical Psychopharmacology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder. (Source: Journal of Clinical Psychopharmacology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.

CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Our results indicate that alcohol and illicit substance use is associated with non-adherence to BUP-naloxone treatment, and suggests that CBT and efforts to promote abstinence from non-opioid substance use may improve adherence among African-Americans. These findings contribute to growing literature on understanding adherence to BUP-naloxone, which is critical to reduce morbidity and mortality. (Am J Addict 2016;XX:1-8).
PMID: 26749158 [PubMed – as supplied by publisher] (Source: American Journal on Addictions)

Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry

Publication date: 20 February 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 120 Author(s): Yongzhen Liu, Xiaohua Li, Allan Xu, Azmi F. Nasser, Christian Heidbreder A simple, sensitive and rapid liquid chromatography/electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS) method was developed and validated for simultaneous quantification of naloxone, buprenorphine and its metabolite norbuprenorphine in human plasma. Human plasma samples were extracted using a single step liquid–liquid extraction, and then separated on an Imtakt Unison UK-C18 column (2.1×50mm, 3μm) using alkaline mobile phases with gradient elution. All of the analytes were detected in positive ion mode using multiple reaction monitoring (MRM). The method was validated and the spe…

Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry

Publication date: 20 February 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 120 Author(s): Yongzhen Liu, Xiaohua Li, Allan Xu, Azmi F. Nasser, Christian Heidbreder A simple, sensitive and rapid liquid chromatography/electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS) method was developed and validated for simultaneous quantification of naloxone, buprenorphine and its metabolite norbuprenorphine in human plasma. Human plasma samples were extracted using a single step liquid–liquid extraction, and then separated on an Imtakt Unison UK-C18 column (2.1×50mm, 3μm) using alkaline mobile phases with gradient elution. All of the analytes were detected in positive ion mode using multiple reaction monitoring (MRM). The method was validated and the spe…